Balancing benefits and risks in the era of biologics

Giovanni Adami*, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guanabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet Geusens

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Article numberARTN 1759720X19883973
Number of pages6
JournalTherapeutic Advances in Musculoskeletal Disease
Volume11
DOIs
Publication statusPublished - Oct 2019

Keywords

  • benefit-risk ratio
  • biologics
  • denosumab
  • romosozumab
  • POSTMENOPAUSAL WOMEN
  • RHEUMATOID-ARTHRITIS
  • CERTOLIZUMAB PEGOL
  • ROMOSOZUMAB
  • PREVENTION
  • INFLIXIMAB
  • FRACTURES
  • DENOSUMAB
  • DISEASES
  • SAFETY

Cite this